Retinal detachment

Nearsightedness is at epidemic levels – and the problem begins in childhood

Retrieved on: 
Thursday, April 25, 2024
Spend, World War II, Growth, Visual perception, Face, Prevalence, Incidence, Risk, School, Research, Optometry, Lens, Infant, Contact, Retinal detachment, Human, Eye, Sunlight, Paratriathlon, Chicken, Book, Parent, Meta-analysis

Some even consider myopia, also known as nearsightedness, an epidemic.

Key Points: 
  • Some even consider myopia, also known as nearsightedness, an epidemic.
  • In the United States alone, spending on corrective lenses, eye tests and related expenses may be as high as US$7.2 billion a year.
  • To answer that question, first let’s examine what causes myopia – and what reduces it.

How myopia develops

  • Optometrists have learned a great deal about the progression of myopia by studying visual development in infant chickens.
  • Just like in humans, if visual input is distorted, a chick’s eyes grow too large, resulting in myopia.
  • The more time we spend focusing on something within arm’s length of our faces, dubbed “near work,” the greater the odds of having myopia.

Outside light keeps myopia at bay

  • A 2022 study, for example, found that myopia rates were more than four times greater for children who didn’t spend much time outdoors – say, once or twice a week – compared with those who were outside daily.
  • In another paper, from 2012, researchers conducted a meta-analysis of seven studies that compared duration of time spent outdoors with myopia incidence.
  • The odds of developing myopia dropped by 2% for each hour spent outside per week.

What’s driving the epidemic

  • Globally, a big part of this is due to the rapid development and industrialization of countries in East Asia over the last 50 years.
  • Around that time, young people began spending more time in classrooms reading and focusing on other objects very close to their eyes and less time outdoors.
  • This is also what researchers observed in the North American Arctic after World War II, when schooling was mandated for Indigenous people.

Treating myopia

  • Fortunately, just a few minutes a day with glasses or contact lenses that correct for blur stops the progression of myopia, which is why early vision testing and vision correction are important to limit the development of myopia.
  • People with with high myopia, however, have increased risk of blindness and other severe eye problems, such as retinal detachment, in which the retina pulls away from the the back of the eye.
  • The chances of myopia-related macular degeneration increase by 40% for each diopter of myopia.


Andrew Herbert receives funding from NSF.

Bausch + Lomb Will Present New Scientific Data and Analyses at the American Society of Cataract and Refractive Surgery Annual Meeting

Retrieved on: 
Wednesday, March 27, 2024
Science, Other Science, Research, Pharmaceutical, Optical, Surgery, General Health, Health, Momentum, YAG, Toric, Failure, IOP, Retinal, Glaucoma, Exercise, DSM-IV codes, Neuropathic pain, ASCRS, History, Sale, Contact, Dry, Refraction, Bausch & Lomb, Eye, System, Keratoconus, Medication discontinuation, Pain, Corneal topography, Telecanthus, Astigmatism, Aphakia, Correction, Uveitis, Surgeon, Diabetes, Risk, Eye injury, CTK, Retinal detachment, Side, Trial of the century, Visual acuity, Diagnosis, Safety, Contraindication, Emmetropia, Vision, Taste, Dry eye syndrome, Intraocular lens, Presbyopia, Real, Floater, Magnetic resonance, Contrast (vision), Human, GLARE, Infection, Use, FDA, Ranibizumab, Muscular dystrophy, Sickle cell disease, Refractive surgery, Retina, Direction, IDE, Allergy, User, Society, Bleeding, Autoimmune disease

In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.

Key Points: 
  • In addition to these scientific presentations, the company will also sponsor educational events focused on these and other Bausch + Lomb products.
  • Bausch + Lomb activities at ASCRS:
    “Assessment of the Spectacle Independence and Visual Outcomes Following Bilateral Implantation of a Novel Toric IOL* Among Cataract Patients.” Harasymowycz et al.
  • “Outcomes of an Ultra-Low Cylinder Powered (0.90 D) Toric versus Non-Toric IOL in Low Astigmatic Patients Undergoing Cataract Surgery.” Muzychuk et al.
  • “Quality of Vision and Clinical Outcomes of a Novel Trifocal IOL* Implanted Bilaterally After Cataract Surgery: A Canadian Multicenter Study.” Harasymowycz et al.

Global Retinal Surgery Devices Markets Forecast to 2030 - Company Profiles, Major Deals, Strategy and Recent Developments, Featuring Alcon, Carl Zeiss Meditec, Iridex, Lumenis, Optos & Nidek - ResearchAndMarkets.com

Retrieved on: 
Friday, February 16, 2024
Optical, Health, Surgery, Medical Devices, Therapy, Diabetic retinopathy, Incidence, Retina, Retinal detachment, Growth, Prevalence, Instrument, Diabetes, Disease, Paratriathlon, Retinal, Vitrectomy, Dentistry

The "Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Company Profiles, Major Deals, Strategy and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Retinal Surgery Devices Market (By Device Segment, Application, Regional Analysis), Company Profiles, Major Deals, Strategy and Recent Developments - Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.
  • The global retinal surgery devices market is projected to reach US$ 4.71 Billion by 2030.
  • The global retinal surgery devices market is mainly driven by the increasing prevalence of ophthalmic conditions, especially diabetic retinopathy.
  • This report has been analyzed from 8 viewpoints:
    Global Retinal Surgery Devices Market - Company Profiles, Major Deals, Strategy, Sales, Recent Developments

Bausch + Lomb Receives FDA Approval for TENEO™ Excimer Laser Platform for Myopia and Myopic Astigmatism LASIK Vision Correction Surgery

Retrieved on: 
Monday, January 8, 2024
FDA, General Health, Optical, Health, IOP, Telecanthus, Patient, Ophthalmology, Failure, Corneal topography, Food, Autoimmune disease, Contraindication, Risk, Floater, Sale, Near-sightedness, CTK, Pain, Retinal detachment, User, Bleeding, Surgeon, Diabetes, Dry, Eye, Side, Dry eye syndrome, Posture, Laser, Visual acuity, Neuropathic pain, Engineering, Infection, Use, Keratoconus, Safety, Magnetic resonance, Bausch & Lomb, Glaucoma, Hospital

Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.

Key Points: 
  • Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. Food and Drug Administration (FDA) has approved the TENEO Excimer Laser Platform for laser-assisted in situ keratomileusis (LASIK) vision correction surgery for myopia and myopic astigmatism (nearsightedness and nearsightedness with astigmatism)*.
  • This feature helps to ensure the laser ablation pattern is not negatively impacted by a patient's eye movement and helps achieve outstanding post-operative outcomes.
  • The platform’s high-speed laser operates at 500Hz, the fastest ablation time of all excimer lasers available in the United States at approximately 1.2 seconds per diopter.
  • “FDA approval of TENEO represents a major milestone for the advancement of laser vision correction technology in the United States,” said George Waring IV, M.D., ophthalmologist and founder and medical director, Waring Vision Institute, Mt.

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Floater, Cataract, Marketing, Protein, BRVO, INN, Neovascularization, Complication, ATC, DME, Endophthalmitis, Retinal detachment, Blood, Bleeding, International, Ranibizumab, AMD, Injection, Disease, Diabetes, Language, CRVO, Eye, Pressure, Swelling, Inflammation, Intraocular pressure, RVO, European Medicines Agency, Infection, Cerebral edema, CNV, Growth, Select, Macular edema, Patient, Safety, Anatomy, Paratriathlon, Retina, IIA, Retinal haemorrhage, Three-body problem, Medical device

Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Yesafili, aflibercept, Date of authorisation: 15/09/2023, Revision: 1, Status: Authorised

Stevie Wonder's We Are You Foundation Supports Wayfinder Family Services

Retrieved on: 
Tuesday, December 26, 2023
Stevie Wonder, Retinal detachment, Cycling, Wayfinder Family Services, Visual impairment, Paratriathlon, Learning, KJLH, Entertainment

LOS ANGELES, Dec. 26, 2023 /PRNewswire/ -- Stevie Wonder's We Are You Foundation CEO Aundrae Russell presented Lucas Pelayo with Wayfinder Family Services' annual Stevie Wonder Star Student Award during the nonprofit's holiday celebration.

Key Points: 
  • LOS ANGELES, Dec. 26, 2023 /PRNewswire/ -- Stevie Wonder's We Are You Foundation CEO Aundrae Russell presented Lucas Pelayo with Wayfinder Family Services' annual Stevie Wonder Star Student Award during the nonprofit's holiday celebration.
  • After the award ceremony, Russell presented a generous donation to Wayfinder, "I toured Wayfinder this morning and there are some amazing things happening here.
  • I am so pleased to present this gift from the We Are You Foundation and Stevie Wonder so that all of this good work can continue changing lives."
  • "Stevie Wonder, the We Are You Foundation and KJLH have been supporting Wayfinder for nearly 20 years.

iVeena Awarded NEI-SBIR Grant For Progressive Myopia Drug Candidate IVMED-85

Retrieved on: 
Thursday, October 26, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Optical, Biotechnology, IND, American Optometric Association, NEI, National Eye Institute, Glaucoma, SBIR, Research and development, Near-sightedness, Doctor of Philosophy, Risk, Retinal detachment, Cornea, Medicinal chemistry, University, Eye, NIH, Cataract

iVeena Delivery Systems Inc. (“iVeena”) , a biopharmaceutical company with a developmental product in pediatric myopia is pleased to announce that Dr. Sarah Molokhia, Vice President of Research & Development for iVeena and Adjunct Assistant Professor at Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah, was awarded a National Eye Institute Phase 1 Small Business Innovative Research (SBIR) grant of $345,000 for iVeena’s progressive myopia control drug candidate IVMED-85.

Key Points: 
  • iVeena Delivery Systems Inc. (“iVeena”) , a biopharmaceutical company with a developmental product in pediatric myopia is pleased to announce that Dr. Sarah Molokhia, Vice President of Research & Development for iVeena and Adjunct Assistant Professor at Department of Pharmaceutics and Pharmaceutical Chemistry at the University of Utah, was awarded a National Eye Institute Phase 1 Small Business Innovative Research (SBIR) grant of $345,000 for iVeena’s progressive myopia control drug candidate IVMED-85.
  • Myopia generally first occurs in school-age children and progresses as the eye grows.
  • IVMED-85 is an experimental topical eye drop that is designed to be administered twice-daily to slow the progression of myopia in children.
  • Dr. Molokhia added that “The NIH and NEI have been extremely supportive of our topical eye drop for treatment of progressive myopia.

Public advisory - Unauthorized health products seized from online retailer "UU Zone" may pose serious health risks

Retrieved on: 
Wednesday, October 25, 2023
Floater, Gland, Stomach, Glaucoma, Viral, Pressure, Health Canada, Dexamethasone, Disease, Risk, Ibuprofen, Allergy, Eye, Red, Nonsteroidal anti-inflammatory drug, Drug identification number, Tuberculosis, Fungal infection, Infection, Sale, Mouth, Burns, Throat, Health, Plasma protein binding, Aspirin, NPN, Rash, Iris cyst, Diabetes, Atrophoderma, Safety, Natural product, Patient, Nose, Prescription drug, Maharashtra University of Health Sciences, Asthma, Triamcinolone, DIN, Pregnancy, Retinal detachment, Pharmacy, Neostigmine, Xeroderma, Cataract, Tropical ulcer, Blurred vision, Herpes simplex, Itch, Skin, Absorption, Inflammation, Common, Hair, NSAID, Myasthenia gravis, Swelling, Weakness, Elasticity, Failure, Dietary supplement, Cosmetics

Health Canada is warning consumers about unauthorized health products it seized from UU Zone, an online retailer, based in Markham, ON.

Key Points: 
  • Health Canada is warning consumers about unauthorized health products it seized from UU Zone, an online retailer, based in Markham, ON.
  • The products are labelled to contain medicinal drugs and may pose serious health risks.
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.
  • Read product labels to verify that health products have been authorized for sale by Health Canada.

Public advisory - Unauthorized health products seized from stores in the Greater Toronto Area because they may pose serious health risks

Retrieved on: 
Wednesday, August 23, 2023
Glaucoma, Retinal detachment, DIN, Elasticity, Hair, Pregnancy, Mouth, Bleeding, Allergy, Prescription drug, Atrophoderma, Xeroderma, Pharmacy, Neostigmine, Blurred vision, Infection, Eye, Weakness, Iris cyst, Health Canada, Cataract, Absorption, Inflammation, Sale, Rash, Plasma protein binding, Itch, Tranexamic acid, Muscle weakness, Nose, NPN, Ranitidine, Dizziness, Nitroglycerin, Aminocaproic acid, Patient, Swelling, Risk, Blood, Drug identification number, Greater Toronto Area, Nausea, Natural product, Health, Headache, Red, Skin, Safety, Hydrochlorothiazide, Common, Dietary supplement

The products are labelled to contain prescription drugs and may pose serious health risks.

Key Points: 
  • The products are labelled to contain prescription drugs and may pose serious health risks.
  • Health Canada is warning consumers about unauthorized Santen brand eye drops that it seized from Asia Food Mart and three L'Amour Beauty locations in the Greater Toronto Area, Ontario.
  • The products are labelled to contain prescription drugs and may pose serious health risks.
  • Unauthorized health products have not been approved by Health Canada, which means that they have not been assessed for safety, efficacy and quality and may pose a range of serious health risks.

EyePoint Pharmaceuticals Presents Interim Masked Safety Data and Patient Baseline Characteristics for DAVIO 2 Clinical Trial at OIS Retina Innovation Summit

Retrieved on: 
Thursday, July 27, 2023
Injection, Maintenance, Interim, Human, Therapy, Anti-VEGF, AMD, Eye, Clinical trial, Șaeș, Patient, Physician, CST, OCT, Retinal detachment, FDA, Visual acuity, Safety, Pharmaceutical industry

WATERTOWN, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a company committed to developing and commercializing therapeutics to improve the lives of patients with serious eye disorders, today announced interim masked safety data and baseline patient demographics from its Phase 2 DAVIO 2 clinical trial of EYP-1901, a potential sustained delivery maintenance treatment for wet age-related macular degeneration (wet AMD). These data are being presented today at the OIS Retina Innovation Summit in Seattle, WA by Nancy Lurker, Executive Vice-Chair of EyePoint Pharmaceuticals.

Key Points: 
  • These data are being presented today at the OIS Retina Innovation Summit in Seattle, WA by Nancy Lurker, Executive Vice-Chair of EyePoint Pharmaceuticals.
  • “Safety is paramount for both patients and physicians in the development of ophthalmic treatments, and these data support EYP-1901’s continued track record of safety in humans.
  • Mean CST in the Phase 2 DAVIO 2 trial was 265 μm, compared to 299 μm in the Phase 1 DAVIO trial.
  • Mean age of patients in the Phase 2 DAVIO 2 trial is 76 years old, compared to 77.4 years old in the Phase 1 DAVIO trial.